Anticoagulation in percutaneous coronary intervention

Brian P. O'Neill, Eric Scot Shaw, Mauricio G Cohen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Balancing safety and efficacy of anticoagulation strategies is a fundamental goal in the performance of percutaneous coronary interventions. The ideal anticoagulant in the catheterization laboratory should effectively prevent thrombosis, yield a low bleeding risk, be titratable to individual clinical needs, be reversible when clinically indicated and be administered without the need for complicated infusions or routine monitoring. Despite its many drawbacks, unfractionated heparin continues to be the most commonly used anticoagulant in percutaneous coronary intervention. Nevertheless, anticoagulation options in the catheterization laboratory have grown substantially over the past 20 years and now include direct thrombin inhibitors, low-molecular-weight heparin molecules and Factor X inhibitors. Additional options are anticipated in the near future with novel agents targeting upstream factors in the coagulation cascade. The availability of multiple anticoagulation options allows for a tailored approach based on the individual patients risk of thrombosis and bleeding. However, multiple anticoagulant choices add complexity in the catheterization laboratory because anticoagulants differ in the mode of administration, monitoring and duration of action. We present a review of current anticoagulation options, novel agents in development and practical issues such as monitoring, switching agents and importance of site access choice.

Original languageEnglish
Pages (from-to)559-577
Number of pages19
JournalInterventional Cardiology
Volume2
Issue number4
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

Percutaneous Coronary Intervention
Anticoagulants
Catheterization
Thrombosis
Hemorrhage
Factor X
Blood Coagulation Factors
Antithrombins
Low Molecular Weight Heparin
Heparin
Safety

Keywords

  • anticoagulant
  • coronary artery disease
  • percutaneous coronary intervention
  • thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Anticoagulation in percutaneous coronary intervention. / O'Neill, Brian P.; Shaw, Eric Scot; Cohen, Mauricio G.

In: Interventional Cardiology, Vol. 2, No. 4, 01.08.2010, p. 559-577.

Research output: Contribution to journalArticle

O'Neill, Brian P. ; Shaw, Eric Scot ; Cohen, Mauricio G. / Anticoagulation in percutaneous coronary intervention. In: Interventional Cardiology. 2010 ; Vol. 2, No. 4. pp. 559-577.
@article{1daf5904af4944a8b64de921f48c2204,
title = "Anticoagulation in percutaneous coronary intervention",
abstract = "Balancing safety and efficacy of anticoagulation strategies is a fundamental goal in the performance of percutaneous coronary interventions. The ideal anticoagulant in the catheterization laboratory should effectively prevent thrombosis, yield a low bleeding risk, be titratable to individual clinical needs, be reversible when clinically indicated and be administered without the need for complicated infusions or routine monitoring. Despite its many drawbacks, unfractionated heparin continues to be the most commonly used anticoagulant in percutaneous coronary intervention. Nevertheless, anticoagulation options in the catheterization laboratory have grown substantially over the past 20 years and now include direct thrombin inhibitors, low-molecular-weight heparin molecules and Factor X inhibitors. Additional options are anticipated in the near future with novel agents targeting upstream factors in the coagulation cascade. The availability of multiple anticoagulation options allows for a tailored approach based on the individual patients risk of thrombosis and bleeding. However, multiple anticoagulant choices add complexity in the catheterization laboratory because anticoagulants differ in the mode of administration, monitoring and duration of action. We present a review of current anticoagulation options, novel agents in development and practical issues such as monitoring, switching agents and importance of site access choice.",
keywords = "anticoagulant, coronary artery disease, percutaneous coronary intervention, thrombosis",
author = "O'Neill, {Brian P.} and Shaw, {Eric Scot} and Cohen, {Mauricio G}",
year = "2010",
month = "8",
day = "1",
doi = "10.2217/ica.10.46",
language = "English",
volume = "2",
pages = "559--577",
journal = "Interventional Cardiology",
issn = "1755-5302",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Anticoagulation in percutaneous coronary intervention

AU - O'Neill, Brian P.

AU - Shaw, Eric Scot

AU - Cohen, Mauricio G

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Balancing safety and efficacy of anticoagulation strategies is a fundamental goal in the performance of percutaneous coronary interventions. The ideal anticoagulant in the catheterization laboratory should effectively prevent thrombosis, yield a low bleeding risk, be titratable to individual clinical needs, be reversible when clinically indicated and be administered without the need for complicated infusions or routine monitoring. Despite its many drawbacks, unfractionated heparin continues to be the most commonly used anticoagulant in percutaneous coronary intervention. Nevertheless, anticoagulation options in the catheterization laboratory have grown substantially over the past 20 years and now include direct thrombin inhibitors, low-molecular-weight heparin molecules and Factor X inhibitors. Additional options are anticipated in the near future with novel agents targeting upstream factors in the coagulation cascade. The availability of multiple anticoagulation options allows for a tailored approach based on the individual patients risk of thrombosis and bleeding. However, multiple anticoagulant choices add complexity in the catheterization laboratory because anticoagulants differ in the mode of administration, monitoring and duration of action. We present a review of current anticoagulation options, novel agents in development and practical issues such as monitoring, switching agents and importance of site access choice.

AB - Balancing safety and efficacy of anticoagulation strategies is a fundamental goal in the performance of percutaneous coronary interventions. The ideal anticoagulant in the catheterization laboratory should effectively prevent thrombosis, yield a low bleeding risk, be titratable to individual clinical needs, be reversible when clinically indicated and be administered without the need for complicated infusions or routine monitoring. Despite its many drawbacks, unfractionated heparin continues to be the most commonly used anticoagulant in percutaneous coronary intervention. Nevertheless, anticoagulation options in the catheterization laboratory have grown substantially over the past 20 years and now include direct thrombin inhibitors, low-molecular-weight heparin molecules and Factor X inhibitors. Additional options are anticipated in the near future with novel agents targeting upstream factors in the coagulation cascade. The availability of multiple anticoagulation options allows for a tailored approach based on the individual patients risk of thrombosis and bleeding. However, multiple anticoagulant choices add complexity in the catheterization laboratory because anticoagulants differ in the mode of administration, monitoring and duration of action. We present a review of current anticoagulation options, novel agents in development and practical issues such as monitoring, switching agents and importance of site access choice.

KW - anticoagulant

KW - coronary artery disease

KW - percutaneous coronary intervention

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=77956149373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956149373&partnerID=8YFLogxK

U2 - 10.2217/ica.10.46

DO - 10.2217/ica.10.46

M3 - Article

AN - SCOPUS:77956149373

VL - 2

SP - 559

EP - 577

JO - Interventional Cardiology

JF - Interventional Cardiology

SN - 1755-5302

IS - 4

ER -